Lung Cancer · Drug Discovery · Precision Oncology

Where Clinical Reality
Meets Drug Discovery

We're building the world's largest patient-derived lung cancer cell bank, spanning all subtypes and treatment stages, to ground therapeutics development and testing in today's clinical reality.

Join Us Learn More

The Problem

The Preclinical Blindspot

Biopharma loses billions annually to a systemic failure hidden in plain sight: preclinical models that don't reflect the real world.

90%

Clinical Trial Failure Rate

The vast majority of drugs that pass preclinical screening ultimately fail in humans — the highest failure rate of any major industry.

$2B+

Average Cost Per Approved Drug

Most of this staggering figure is driven by failures: candidates that should never have advanced past the preclinical stage.

Homogenous.
Treatment-naive.
Unrepresentative.

The State of Current Models

Standard cell lines and animal models ignore clinical diversity and exclude treatment-experienced patients.

Our Approach

Built for Clinical Reality

An end-to-end platform built to close the loop from patient biology to validated therapeutic insight.

Anemos Atlas

The World's Most Representative Cell Bank

Patient-derived lung cancer cell lines spanning all subtypes, demographic groups, and treatment stages, built to reflect the full complexity of real patient populations, not the narrow, treatment-naive slice that standard vendors offer.

Anemos Data & AI

Predictions Grounded in Real Biology

A computational suite that leverages multimodal clinical and cellular data to generate predictive insights and novel targets. Unlike pure-AI approaches, our predictions can be biologically confirmed in our own cell lines, not just modeled.

Our Team

Driven by Urgency. Built for Scale.

Merging computational biology, clinical urgency, and commercial execution.

Minseung Choi

Co-Founder & CTO

Architect of Anemos Atlas and our computational data pipelines. Brings deep expertise in computational biology and data systems to build the engine that powers the entire platform.

Sanjay Pothen

Co-Founder & CEO

Seasoned biotech operator leading commercial scaling and revenue strategy. Translates scientific excellence into sustainable, partnership-driven growth.

Bryant Lin, MD

Co-Founder

Physician, engineer, and entrepreneur — and a Stage IV lung cancer patient himself. Grounds every decision in clinical reality and guides our biological focus with firsthand urgency.

Get in Touch

Join us in accelerating breakthroughs for lung cancer patients worldwide.